We anticipate the retail experience evolving, such that consumers will easily recognize
the unmatched quality of indoor grown cannabis
MONCTON, NB, Nov. 29, 2017 /CNW/ - Drawing on years of
innovation and research, and a deep understanding of the potential of the cannabis plant, Organigram Holdings Inc. (TSX
VENTURE:OGI) (OTCQB:OGRMF) (the "Company" or "Organigram"), a leading licensed producer of medical marijuana based in
Moncton, New Brunswick, today launched The Edison Project. The Edison Project is an initiative
designed to produce and offer Organigram patients the very highest quality flower possible using the latest in technology and
industry best practices.
"The Edison Project represents our very best work to date," says Ray Gracewood, Organigram's
Chief Commercial Officer. "We're most proud of these strains of medicine because they're a product of our intensive research on
the biology of cannabis and continuous improvement in production. We've adopted a culture of refusing to settle at
Organigram; it's evolved such that we've come to discover more about the true potential in our plants and we've learned how to
deliver the benefit of that potential to our patients."
What's New:
The Edison Project produces cannabis differentiated by three key characteristics:
- Top flower: In the cannabis world, no part of the plant is more valuable than the top flower. Lower branches are
pruned frequently throughout the flowering stage to assist the plant in funneling its energy resources to the top, which helps
maximize robust top flower production. Because they grow at the very highest point, Edison flowers absorb the most light energy
available to the plant resulting in a more lush flower.
- Hand-manicured: Edison flowers are individually hand-manicured, a process during which technicians personally
inspect, handle and tailor each one to remove as much stem and leaf, while retaining as many trichomes as possible. Trimmers
thoroughly inspect each flower and apply the precision and attention it deserves. Hand-manicured flowers represent the highest
quality whole-flower cannabis produced at the Organigram facility.
- Craft cured: While growing cannabis to the highest possible standard is essential, it's only half the story;
achieving exceptional quality depends on how cannabis is cured after harvest. Intentionally aging with patience and respect for
the plant's evolutionary process results in cannabis that's more complex and complete. Edison flower is cured in a process
which ensures each strain is treated with the optimal temperature and humidity for its individual needs. Flowers are cured in
small batches and allowed to breathe longer, resulting in greater chlorophyll breakdown and a distinct, alluring flavour and
aroma.
"At Organigram, we pride ourselves on building a culture of growth and innovation," says Greg
Engel, CEO, Organigram. "The Edison Project reflects our commitment to continually evolving our own team's expertise and
delivering a second-to-none cannabis experience for patients. We anticipate the retail experience evolving, such that consumers
will easily recognize the unmatched quality of indoor grown cannabis and post-harvest, hand-treated flower. The Edison Project
represents both these elements very well, and we're thrilled to introduce it to patients."
The first two Edison Project by OGI products – #3 Edison and #7 Edison – are now available to registered patients of
Organigram as of Monday, Nov. 27.
For more information on The Edison Project by OGI, please visit www.organigram.ca/edison.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest
quality, condition specific medical marijuana for patients in Canada. Organigram's facility is
located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for
Medical Purposes Regulations ("ACMPR").
Organigram has been ranked in the top ten Clean Technology & Life Sciences Sector on the TSX Venture Exchange
50.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current expectations. Important factors - including the availability of
funds, consummation of definitive documentation, the results of financing efforts, crop yields - that could cause actual results
to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR
(see www.sedar.com). Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
For more information, visit www.Organigram.ca
SOURCE OrganiGram
View original content with multimedia: http://www.newswire.ca/en/releases/archive/November2017/29/c5523.html